Sosei pens inflammatory and autoimmune disease drug pact with AbbVie

Sosei Heptares saw its shares shoot up around 12% in Tokyo this morning on news it has signed a new pact with AbbVie.

The biopharma is getting $32 million upfront for an exclusive early-stage discovery collab, including an option for a license agreement, to create and sell up to four therapies that modulate G protein-coupled receptor (GPCR) targets “of interest to AbbVie.”